Most clinicians do not need another explanation of prior authorization. They live with it every day. You pick the medication. You send the prescription. The plan makes clinical sense. Then the pharmacy calls. Or the patient messages. Or the fax arrives: "Prior authorization required." Prior authorization is meant to confirm that a medication, test, procedure, or service meets payer coverage criteria before approval. In practice, it often creates a gap between the clinical decision and the patient actually starting treatment. And that gap matters.
A 2025 systematic review in The American Journal of Medicine found that prior authorization has been associated with delayed care, reduced clinical effectiveness, and compromised patient outcomes across multiple specialties. So the useful question is not why prior authorization is frustrating — we know. The better question is: what can clinicians do before the first denial to reduce avoidable delays?
For patients, prior authorization is about access. When an appropriate medication is delayed, symptoms may worsen, disease control may stall, or the patient may abandon therapy altogether because the process feels too confusing or slow. This is especially true for specialty medications, biologics, high-cost branded therapies, and drugs subject to step therapy. The prescription may be clinically appropriate, but if the request does not clearly show why it meets the payer's criteria, it can still get delayed or denied.
Prior authorization delays often start with incomplete or mismatched information. The diagnosis is there, but the severity is not. The medication history is mentioned, but not specific. The patient 'failed prior therapy,' but the payer cannot tell which therapy, at what dose, for how long, or why it failed. A 2024 Health Affairs Scholar study found that patients, clinicians, and payers all experience meaningful friction in the prior authorization process, with clinicians and staff absorbing substantial workflow burden.
A prior authorization request should not make the reviewer hunt for the clinical story. Include the diagnosis, relevant ICD-10 code, disease severity, symptom burden, and objective findings when available. Depending on the specialty, that might mean body surface area, disease activity score, prior biopsy results, inflammatory markers, A1c trend, blood pressure history, imaging results, functional impairment, or recent flares and hospitalizations. The goal is simple: make the medical necessity obvious to someone who was not in the room with the patient.
Many denials happen because the payer cannot confirm that the patient tried the preferred alternatives. "Failed prior therapy" is vague. "Trialed methotrexate 15 mg weekly for 12 weeks; discontinued due to elevated transaminases" is useful. Whenever possible, include the medication name, dose, duration, response, intolerance, contraindication, and reason for discontinuation. Think of it as leaving breadcrumbs for approval — very specific, payer-friendly breadcrumbs.
Step therapy denials often happen when the request bypasses a preferred agent without clearly explaining why. If the preferred medication was ineffective, not tolerated, or contraindicated because of comorbidities, renal function, pregnancy considerations, drug interactions, disease severity, or prior adverse events, say so explicitly. A sentence like this can help: "Preferred formulary therapy is not appropriate because the patient previously experienced [specific adverse effect], and rechallenge is not recommended given [clinical reason]." Clear beats clever here, every time.
Patients often hear "your prescription was sent" and assume the medication will be ready that day. A little expectation-setting helps: "This medication may require insurance approval. That does not mean it was denied. It means we may need to send additional clinical information before the pharmacy can fill it." Then give them a next step: "If the pharmacy says it needs approval, please call or message us. Do not just walk away from it."
Pharmacists often see the access problem first — the rejection code, formulary issue, specialty pharmacy requirement, or the patient who says they thought it was already sent. Pharmacists can help distinguish between a true clinical denial and an administrative barrier that may be fixable with better documentation, a covered alternative, copay support, or patient assistance. A denial is not always the end of the road. Sometimes it is a request for a better map.
Electronic prior authorization can reduce manual steps and improve visibility earlier in the prescribing workflow. Research in JAMA Network Open found that clinically integrated prior authorization software was associated with lower denial rates, shorter authorization times, and improved staff satisfaction. Federal policy is also moving toward real-time prescription benefit information and electronic prior authorization. But technology does not replace clinical documentation. If the request lacks diagnosis detail, prior therapy history, severity, or medical necessity language, the process can still stall.
Prior authorization is not just a payer process — it is a treatment-access process. Clinicians may not be able to eliminate prior authorization, but they can reduce avoidable delays by making the clinical case clear the first time: document the diagnosis, show the severity, list prior therapies, explain step therapy exceptions, set expectations with the patient, and loop in pharmacists early. Because the goal is not simply to win an approval. The goal is to help the patient start clinically appropriate therapy without unnecessary delay.
